SCLnow 19
/ Sclnow Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
60
Go to page
1
2
3
December 05, 2025
SCLife®-LDD hUC-MSCs Injection Therapy for Patients With Lumbar Intervertebral Disc Degeneration
(clinicaltrials.gov)
- P1 | N=20 | Suspended | Sponsor: Sclnow Biotechnology Co., Ltd. | Trial completion date: Jun 2026 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Jun 2026
Trial completion date • Trial primary completion date • Musculoskeletal Diseases
December 05, 2025
Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia
(clinicaltrials.gov)
- P2 | N=45 | Not yet recruiting | Sponsor: Sclnow Biotechnology Co., Ltd. | Trial primary completion date: Dec 2025 ➔ Jun 2026
Trial primary completion date • Ataxia • Movement Disorders
December 05, 2025
The Safety/Efficacy of hUC Mesenchymal Stem Cells(19#iSCLife®-OA) Therapy for Patients With Osteoarthritis
(clinicaltrials.gov)
- P2 | N=60 | Recruiting | Sponsor: Sclnow Biotechnology Co., Ltd. | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Jun 2025 ➔ Jun 2026
Trial completion date • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology
November 25, 2025
hUC Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosishepatitis b Cirrhosis
(clinicaltrials.gov)
- P1 | N=20 | Recruiting | Sponsor: Sclnow Biotechnology Co., Ltd. | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Jun 2025 ➔ Dec 2025
Trial completion date • Trial primary completion date • Fibrosis • Hepatitis B • Immunology • Infectious Disease • Inflammation
May 22, 2025
hUC Mesenchymal Stem Cells (19#iSCLife®-UT) Therapy for Patients With Thin Endometrial Infertility
(clinicaltrials.gov)
- P1 | N=25 | Completed | Sponsor: Sclnow Biotechnology Co., Ltd. | Recruiting ➔ Completed
Trial completion • Infertility • Sexual Disorders
May 14, 2025
hUC Mesenchymal Stem Cells (19#iSCLife®-UT) Therapy for Patients With Thin Endometrial Infertility
(clinicaltrials.gov)
- P1 | N=24 | Recruiting | Sponsor: Sclnow Biotechnology Co., Ltd. | Trial completion date: Apr 2025 ➔ Jun 2026 | Trial primary completion date: Mar 2025 ➔ Dec 2025
Trial completion date • Trial primary completion date • Infertility • Sexual Disorders
April 07, 2025
Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia
(clinicaltrials.gov)
- P2 | N=45 | Not yet recruiting | Sponsor: Sclnow Biotechnology Co., Ltd. | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Jun 2025 ➔ Dec 2025
Trial completion date • Trial primary completion date • Ataxia • Movement Disorders
April 07, 2025
The Safety/Efficacy of hUC Mesenchymal Stem Cells(19#iSCLife®-OA) Therapy for Patients With Osteoarthritis
(clinicaltrials.gov)
- P2 | N=60 | Recruiting | Sponsor: Sclnow Biotechnology Co., Ltd. | Trial completion date: Jun 2025 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Jun 2025
Trial completion date • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology
April 04, 2025
The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
(clinicaltrials.gov)
- P2 | N=12 | Suspended | Sponsor: Sclnow Biotechnology Co., Ltd. | Trial completion date: Jun 2025 ➔ Jun 2026 | Trial primary completion date: Dec 2024 ➔ Dec 2025
Trial completion date • Trial primary completion date • Women's Health
March 19, 2025
Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome (MDS)
(clinicaltrials.gov)
- P1/2 | N=40 | Suspended | Sponsor: Sclnow Biotechnology Co., Ltd. | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Jun 2025 ➔ Jun 2026
Trial completion date • Trial primary completion date • Hematological Malignancies • Myelodysplastic Syndrome • Oncology
March 19, 2025
The Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ACI) in the Treatment of Acute Cerebral Infarction
(clinicaltrials.gov)
- P1 | N=40 | Suspended | Sponsor: Sclnow Biotechnology Co., Ltd. | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Jun 2025 ➔ Jun 2026
Trial completion date • Trial primary completion date • CNS Disorders
March 19, 2025
The Study of Early Stage Osteonecrosis of Femoral Head With Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ONFH)
(clinicaltrials.gov)
- P1/2 | N=30 | Suspended | Sponsor: Sclnow Biotechnology Co., Ltd. | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Jun 2025 ➔ Jun 2026
Trial completion date • Trial primary completion date
March 19, 2025
The Study of Heart Failure With Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-HF)
(clinicaltrials.gov)
- P1/2 | N=60 | Suspended | Sponsor: Sclnow Biotechnology Co., Ltd. | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Jun 2025 ➔ Jun 2026
Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure
March 19, 2025
Human Umbilical Cord Mesenchymal Stem Cell Therapy (19#iSCLife®-CI) for Cerebral Infarction Patients in Convalescent Period.
(clinicaltrials.gov)
- P1/2 | N=40 | Suspended | Sponsor: Sclnow Biotechnology Co., Ltd. | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Jun 2025 ➔ Jun 2026
Trial completion date • Trial primary completion date • CNS Disorders
December 09, 2024
SCLife®-LDD hUC-MSCs Injection Therapy for Patients With Lumbar Intervertebral Disc Degeneration
(clinicaltrials.gov)
- P1 | N=20 | Suspended | Sponsor: Sclnow Biotechnology Co., Ltd. | Trial completion date: Dec 2025 ➔ Jun 2026 | Initiation date: Oct 2024 ➔ Jun 2025 | Recruiting ➔ Suspended | Trial primary completion date: Jun 2025 ➔ Dec 2025
Trial completion date • Trial initiation date • Trial primary completion date • Trial suspension • Musculoskeletal Diseases
September 21, 2024
SCLife®-LDD hUC-MSCs Injection Therapy for Patients With Lumbar Intervertebral Disc Degeneration
(clinicaltrials.gov)
- P1 | N=20 | Recruiting | Sponsor: Sclnow Biotechnology Co., Ltd.
New P1 trial • Musculoskeletal Diseases
July 22, 2024
hUC Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosishepatitis b Cirrhosis
(clinicaltrials.gov)
- P1 | N=20 | Recruiting | Sponsor: Sclnow Biotechnology Co., Ltd. | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Jun 2024 ➔ Jun 2025
Trial completion date • Trial primary completion date • Fibrosis • Hepatitis B • Hepatology • Immunology • Infectious Disease • Inflammation
April 19, 2024
The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
(clinicaltrials.gov)
- P2 | N=12 | Suspended | Sponsor: Sclnow Biotechnology Co., Ltd. | Trial completion date: Dec 2024 ➔ Jun 2025 | Trial primary completion date: Dec 2023 ➔ Dec 2024
Trial completion date • Trial primary completion date • Women's Health
April 19, 2024
Human Umbilical Cord Mesenchymal Stem Cell Therapy (19#iSCLife®-CI) for Cerebral Infarction Patients in Convalescent Period.
(clinicaltrials.gov)
- P1/2 | N=40 | Suspended | Sponsor: Sclnow Biotechnology Co., Ltd. | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Jun 2024 ➔ Jun 2025
Trial completion date • Trial primary completion date • CNS Disorders
April 19, 2024
The Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ACI) in the Treatment of Acute Cerebral Infarction
(clinicaltrials.gov)
- P1 | N=40 | Suspended | Sponsor: Sclnow Biotechnology Co., Ltd. | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Jun 2024 ➔ Jun 2025
Trial completion date • Trial primary completion date • CNS Disorders
April 19, 2024
hUC Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosishepatitis b Cirrhosis
(clinicaltrials.gov)
- P1 | N=20 | Recruiting | Sponsor: Sclnow Biotechnology Co., Ltd. | Trial completion date: Jun 2024 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Jun 2024
Trial completion date • Trial primary completion date • Fibrosis • Hepatitis B • Hepatology • Immunology • Infectious Disease • Inflammation
April 19, 2024
The Study of Heart Failure With Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-HF)
(clinicaltrials.gov)
- P1/2 | N=60 | Suspended | Sponsor: Sclnow Biotechnology Co., Ltd. | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Jun 2024 ➔ Jun 2025
Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure
April 19, 2024
Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia
(clinicaltrials.gov)
- P2 | N=45 | Not yet recruiting | Sponsor: Sclnow Biotechnology Co., Ltd. | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Jun 2024 ➔ Jun 2025
Trial completion date • Trial primary completion date • Ataxia • Movement Disorders
April 19, 2024
The Study of Early Stage Osteonecrosis of Femoral Head With Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ONFH)
(clinicaltrials.gov)
- P1/2 | N=30 | Suspended | Sponsor: Sclnow Biotechnology Co., Ltd. | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Jun 2024 ➔ Jun 2025
Trial completion date • Trial primary completion date
April 19, 2024
Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome (MDS)
(clinicaltrials.gov)
- P1/2 | N=40 | Suspended | Sponsor: Sclnow Biotechnology Co., Ltd. | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Jun 2024 ➔ Jun 2025
Trial completion date • Trial primary completion date • Hematological Malignancies • Myelodysplastic Syndrome • Oncology
1 to 25
Of
60
Go to page
1
2
3